Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland,Journal of the European Academy of Dermatology and Venereology

当前位置： X-MOL 学术 › J. Eur. Acad. Dermatol. Venereol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Journal of the European Academy of Dermatology and Venereology ( IF 9.2 ) Pub Date : 2022-11-25 , DOI: 10.1111/jdv.18779
Katharina Schumann ₁ , Cornelia Mauch ₂ , Kai-Christian Klespe ₂ , Carmen Loquai ₃ , Ulrike Nikfarjam ₃ , Max Schlaak ₄ , Larissa Akçetin ₅ , Peter Kölblinger ₆ , Magdalena Hoellwerth ₆ , Markus Meissner ₇ , Guelcin Mengi ₇ , Andreas Dominik Braun ₈ , Miriam Mengoni ₈ , Reinhard Dummer ₉ , Joanna Mangana ₉ , Mihaela-Anca Sindrilaru ₁₀ , Dan Radmann ₁₀ , Christine Hafner ₁₁ , Johann Freund ₁₁ , Klemens Rappersberger ₁₂ , Felix Weihsengruber ₁₂ , Frank Meiss ₁₃ , Lydia Reinhardt _{14,

15} , Friedegund Meier _{14,

15} , Barbara Rainer ₁₆ , Erika Richtig ₁₆ , Julia Maria Ressler ₁₇ , Christoph Höller ₁₇ , Thomas Eigentler _{4,

18} , Teresa Amaral ₁₈ , Wiebke K Peitsch ₁₉ , Uwe Hillen ₂₀ , Wolfgang Harth ₂₁ , Fabian Ziller ₂₂ , Kerstin Schatton ₂₃ , Thilo Gambichler ₂₄ , Laura Susok ₂₄ , Lara Valeska Maul ₂₅ , Heinz Läubli ₂₆ , Dirk Debus ₂₇ , Carsten Weishaupt ₂₈ , Sevil Börger ₂₉ , Katharina Sievers ₂₉ , Sebastian Haferkamp ₃₀ , Veronika Zenderowski ₃₀ , Van Anh Nguyen ₃₁ , Marina Wanner ₃₁ , Ralf Gutzmer ₃₂ , Patrick Terheyden ₃₃ , Katharina Kähler ₃₄ , Steffen Emmert ₃₅ , Alexander Thiem ₃₅ , Michael Sachse ₃₆ , Silke Gercken-Riedel ₃₆ , Kjell Matthias Kaune ₃₇ , Kai-Martin Thoms ₃₈ , Lucie Heinzerling _{5,

39} , Markus Vincent Heppt ₃₉ , Sabine Tratzmiller ₄₀ , Wolfram Hoetzenecker ₄₁ , Angela Öllinger ₄₁ , Andreas Steiner ₄₂ , Tobias Peinhaupt ₄₂ , Maurizio Podda ₄₃ , Sabine Schmid ₄₃ , Uwe Wollina ₄₄ , Tilo Biedermann ₁ , Christian Posch _{1,

45,

46}

Affiliation

Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Munich, Germany.
Department for Dermatology and Venereology and CIO ABCD, University Hospital Köln, Köln, Germany.
Department for Dermatology, Johannes Gutenberg-University Mainz, Mainz, Germany.
Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Department for Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany.
Department for Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria.
Department for Dermatology, University Clinic Frankfurt, Frankfurt, Germany.
Department of Dermatology, University Hospital Magdeburg, Magdeburg, Germany.
Dermatology Clinic, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Department for Dermatology and Allergy, University Clinic Ulm, Ulm, Germany.
Department of Dermatology, University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, St. Pölten, Austria.
Department for Dermatology, Municipal Hospital Landstrasse, Vienna, Austria.
Department for Dermatology and Venereology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases, Dresden, Germany.
Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Department of Dermatology and Venereology, Medical University Graz, Graz, Austria.
Department of Dermatology, Medical University Vienna, Vienna, Austria.
Department of Dermatology, Interdisciplinary Skin Cancer Center, University Medical Center Tuebingen, Tuebingen, Germany.
Departments of Dermatology and Phlebology, Vivantes Skin Cancer Center, Vivantes Clinic Friedrichshain, Neukölln and Spandau, Berlin, Germany.
Department of Dermatology and Venereology, Vivantes Skin Cancer Center, Klinikum Neukölln, Berlin, Germany.
Department of Dermatology and Allergology, Vivantes Skin Cancer Center, Klinikum Spandau, Berlin, Germany.
Department for Dermatology, DRK Hospital Chemnitz-Rabenstein, Chemnitz, Germany.
Department for Dermatology, University Clinic Düsseldorf, Düsseldorf, Germany.
Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, Bochum, Germany.
Department for Dermatology, University Hospital Basel, Basel, Switzerland.
Department for Oncology, University Hospital Basel, Basel, Switzerland.
Department of Dermatology, Nuremberg General Hospital - Paracelsus Medical University, Nuremberg, Germany.
Department for Dermatology and Venereology, University Clinic Münster, Münster, Germany.
Clinic for Dermatology, Kassel, Germany.
Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
Department for Dermatology, Venereology and Allergology, Medical University Innsbruck, Innsbruck, Austria.
Department of Dermatology, Mühlenkreiskliniken Minden und Ruhr University Bochum, Minden, Germany.
Department for Dermatology and Venereology, University Clinic Schleswig-Holstein, Lübeck, Germany.
Department for Dermatology and Venereology, University Clinic Schleswig-Holstein, Kiel, Germany.
Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.
Department for Dermatology, Clinic Bremerhaven Reinkenheide, Bremerhaven, Germany.
Dermatology, Dermatosurgery and Allergology Clinic, Bremen-Mitte Hospital, Bremen, Germany.
Department for Dermatology, University Hospital Göttingen, Georg-August-University, Göttingen, Germany.
Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg and Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg, Erlangen, Germany.
Department for Dermatology, Municipal Hospital Karlsruhe, Karlsruhe, Germany.
Department of Dermatology, University Hospital Linz, Johannes Kepler University, Linz, Austria.
Municipal Hospital Hietzing, Vienna, Austria.
Department for Dermatology, Clinic Darmstadt, Darmstadt, Germany.
Department for Dermatology and Allergology, Municipal Hospital Dresden, Dresden, Germany.
Faculty of Medicine, Sigmund Freud University Vienna, Vienna, Austria.
Department for Dermatology, Clinic Hietzing, Vienna Healthcare Group, Vienna, Austria.

Programmed death-1 (PD-1) antibodies and BRAF + MEK inhibitors are widely used for adjuvant therapy of fully resected high-risk melanoma. Little is known about treatment efficacy outside of phase III trials. This real-world study reports on clinical outcomes of modern adjuvant melanoma treatment in specialized skin cancer centers in Germany, Austria and Switzerland.

中文翻译：

德国、奥地利和瑞士 39 个皮肤癌中心使用 PD-1 抗体和 BRAF + MEK 抑制剂辅助治疗黑色素瘤的真实世界结果

程序性死亡-1 (PD-1) 抗体和 BRAF + MEK 抑制剂广泛用于完全切除的高危黑色素瘤的辅助治疗。除了 III 期试验外，人们对治疗效果知之甚少。这项真实世界的研究报告了在德国、奥地利和瑞士的专业皮肤癌中心进行的现代黑色素瘤辅助治疗的临床结果。

更新日期：2022-11-25

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>